Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02580981 · ClinicalTrials.gov registry record · NA
Acute Lymphoblastic Leukemia Therapies Informed by Genomic Analyses
A NA study, sponsored by New Mexico Cancer Research Alliance.
- Terminated
- Registry status
- NA
- Development phase
- 21
- Enrollment target
NCT02580981 is a NA study that was terminated before completion, run by New Mexico Cancer Research Alliance. The registered enrollment target is 21 participants.
The verdict
NCT02580981, a NA study, was terminated before completion, sponsored by New Mexico Cancer Research Alliance.
- TERMINATED
- Registry status
- NA
- Development phase
- 21 participants
- Enrollment target
Study Summary
Previous work performed by University of New Mexico Comprehensive Cancer Center (UNMCCC) investigators has revealed previously unknown genomic mutations in children, adolescents, and young adults with high-risk B and T cell precursor acute lymphoblastic leukemia (ALL). Using genomic and next generation DNA sequencing technologies, these investigators revealed that 14% of children with high-risk ALL have "Philadelphia chromosome-like" ("Ph-like") ALL. Patients with this form of ALL were found to have a significantly increased risk of treatment failure and death. Further work revealed that there are more than 40 distinct gene rearrangements and fusions that can result in Ph-like ALL. Cell lines and human leukemic cells expressing some of these different gene fusions were sensitive to currently available drugs. This suggests that Ph-like ALL patients with these specific distinct gene fusions should be targeted in future clinical trials to be treated with appropriate therapy. Further work is also needed to identify other potentially targetable genetic alterations in ALL patients. Therefore, the goal of this study is to perform genomic screening of all newly diagnosed ALL patients seen at UNM and to use this information to enroll patients onto available National Clinical Trial Network (NCTN) clinical trials. If an appropriate NCTN trial is not available, best clinical management will be pursued.
Interventions
- OTHER Acute Lymphobastic Leukemia (ALL) Treatment Options
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2016-07-28 |
| Est. Completion | 2022-10-20 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02580981
The ClinicalTrials.gov registry entry for NCT02580981 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New Mexico Cancer Research Alliance, which has 66 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Acute Lymphobastic Leukemia (ALL) Treatment Options is the first listed.
NCT02580981 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02580981 about?
NCT02580981 is a clinical study titled "Acute Lymphoblastic Leukemia Therapies Informed by Genomic Analyses". Previous work performed by University of New Mexico Comprehensive Cancer Center (UNMCCC) investigators has revealed previously unknown genomic mutations in children, adolescents, and young adults with high-risk B and T cell precursor acute lymphoblastic leukemia (ALL). Using genomic and next generat...
What is the current status of trial NCT02580981?
This trial is currently terminated. It is a NA study. The enrollment target is 21 participants. The study started on 2016-07-28. Estimated completion is 2022-10-20.
What interventions are being tested in trial NCT02580981?
The interventions under investigation include: Acute Lymphobastic Leukemia (ALL) Treatment Options (OTHER).
Who is sponsoring clinical trial NCT02580981?
This trial is sponsored by New Mexico Cancer Research Alliance, which has 66 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.